Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Systems and processes for operating an intelligent automated assistant are provided. In one example process, discourse input representing a user request can be received. The process can determine one or more possible device characteristics corresponding to the discourse input. Data structure representing a set of devices of an established location can be retrieved. The process can determine, based on the data structure, one or more candidate devices from the set of devices. The one or more candidate devices can correspond to the discourse input. The process can determine, based on the one or more possible device characteristics and one or more actual device characteristics of the one or more candidate devices, a user intent corresponding to the discourse input. Instructions that cause a device of the one or more candidate devices to perform an action corresponding to the user intent can be provided.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Some embodiments provide techniques performed by at least one voice agent. The techniques include receiving voice input; identifying at least one application program as relating to the received voice input; and displaying at least one selectable visual representation that, when selected, causes focus of the computing device to be directed to the at least one application program identified as relating to the received voice input.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Systems and processes for operating an intelligent automated assistant are provided. In one example process, discourse input representing a user request is received. The process determines whether the discourse input relates to a device of an established location. In response to determining that the discourse input relates to a device of an established location, a data structure representing a set of devices of the established location is retrieved. The process determines, using the data structure, a user intent corresponding to the discourse input, the user intent associated with an action to be performed by a device of the set of devices, and a criterion to be satisfied prior to performing the action. The action and the device are stored in association with the criterion, where, in accordance with a determination that the criterion is satisfied, the action is performed by the device.

Abstract: Systems and processes for operating an intelligent automated assistant are provided. In one example process, discourse input representing a user request can be received. The process can determine one or more possible device characteristics corresponding to the discourse input. Data structure representing a set of devices of an established location can be retrieved. The process can determine, based on the data structure, one or more candidate devices from the set of devices. The one or more candidate devices can correspond to the discourse input. The process can determine, based on the one or more possible device characteristics and one or more actual device characteristics of the one or more candidate devices, a user intent corresponding to the discourse input. Instructions that cause a device of the one or more candidate devices to perform an action corresponding to the user intent can be provided.

Abstract: A system comprising at least one processor configured to perform: receiving a first request to access a first user profile of a first user from a first device configured to execute a first virtual assistant to interact with the first user; in response to receiving the first request, providing the first device with access to information in the first user profile so that the first virtual assistant is able to customize, based on the accessed information, its behavior when interacting with the first user; receiving a second request to access the first user profile from a second device configured to execute a second virtual assistant to interact with the first user; and in response to receiving the second request, providing the second device with access to the information so that the second virtual assistant is able to customize, based on the accessed information, its behavior when interacting with the first user.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Some embodiments relate to techniques for receiving a query from a device, the query comprising content; determining based at least in part on the content of the query that an application is to be launched on the device; and causing the device to launch the application using at least some information determined from the content of the query. Some embodiments relate to techniques for receiving a free-form query from a user; transferring a representation of the query to at least one computer; and receiving from the at least one computer at least one instruction to launch an application on the device.

Abstract: Some embodiments relate to techniques for receiving a query from a device, the query comprising content; determining based at least in part on the content of the query that an application is to be launched on the device; and causing the device to launch the application using at least some information determined from the content of the query. Some embodiments relate to techniques for receiving a free-form query from a user; transferring a representation of the query to at least one computer; and receiving from the at least one computer at least one instruction to launch an application on the device.

Abstract: A mobile device comprising at least one computer-readable storage medium configured to store user profile information of a user of the mobile device; and at least one processor, coupled to the at least one computer-readable storage medium, configured to perform an act of: providing a second device, which is configured to execute a first virtual assistant, with access to at least some of the user profile information so that the first virtual assistant is able to customize, based on the at least some user profile information, its behavior when interacting with the user.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: A mobile device comprising at least one computer-readable storage medium configured to store user profile information of a user of the mobile device; and at least one processor, coupled to the at least one computer-readable storage medium, configured to perform an act of: providing a second device, which is configured to execute a first virtual assistant, with access to at least some of the user profile information so that the first virtual assistant is able to customize, based on the at least some user profile information, its behavior when interacting with the user.